Clinical trials
Lung Cancer (NSCLC) clinical trials
Below are recruiting lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 1,079 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07220096Recruiting
Registry for young adults with lung cancer
This study is for people diagnosed with lung cancer at a younger age (under 50). It aims to understand your needs and improve care through a dedicated program. You will be asked to complete surveys about your experience.
Houston, TexasAges 18–50 - NCT04789486RecruitingPhase 1/Phase 2
MR-guided radiation plus nanoparticles for central lung or pancreatic tumors
This early-phase study tests a new way to deliver focused radiation using MRI guidance and tiny particles, aiming to treat certain central lung tumors or locally advanced pancreatic cancer. It’s designed to see how safe it is and how well it can control these tumors.
Boston, MassachusettsAges 18 years+ - NCT07565532Recruiting
Small Cell Lung Cancer Treatment Study With Radiation
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06436625Recruiting
Outpatient rehab for lung cancer patients on immunotherapy
This study tests whether a structured outpatient exercise program can help people with non-small cell lung cancer who are already receiving immunotherapy. It is designed for those whose cancer is stable or responding after initial treatment.
ViennaAges 18–120 - NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT07668037Recruiting
Understanding long-term survival in NSCLC immunotherapy
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
BeijingAges 18 years+ - NCT05358548RecruitingPhase 2
Alternating treatment for advanced lung and head-neck cancers
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
Elizabeth, New JerseyAges 18 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT07629375Recruiting
Creating Research Models From Your Lung Cancer Tissue
This study collects lung cancer tissue samples from patients undergoing surgery to create laboratory models that help researchers test new treatments. Your participation helps advance personalized cancer medicine for future patients.
Rome, RomeAges 18 years+ - NCT07478809Recruiting
Long-term study of RATIONALE-307 trial participants
This study looks back at people who took part in the RATIONALE-307 trial for a type of lung cancer called squamous non-small cell lung cancer. It aims to learn more about their health outcomes over time by only including those who were still alive when the original trial ended.
BeijingAges Any age - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT05636969Recruiting
Pre-surgery exercise program for lung cancer treatment
This trial looks at whether a “prehabilitation” (guided exercise and fitness preparation) program helps people with non-small cell lung cancer get ready for surgery after starting treatment before surgery. It may help you tolerate treatment and surgery better if you can do the required fitness testing and procedures.
Barcelona, BarcelonaAges 18 years+ - NCT06428422Recruiting
Probiotic supplement for advanced lung cancer
This trial tests if taking a probiotic supplement along with your standard lung cancer treatment can help you live longer and respond better to therapy. It is for people with advanced non-small cell lung cancer who have not tried immunotherapy before.
KonyaAges 19–90 - NCT05766800RecruitingPhase 2
PD-1 plus chemotherapy before surgery for advanced lung cancer
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
ShanghaiAges 18 years+ - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT07617337RecruitingPhase 1
New drug for ALK-positive lung cancer
This trial tests a new oral medication called AQUA07 for people with a specific type of lung cancer (ALK-positive non-small cell lung cancer) that has grown or spread despite prior treatment with certain targeted drugs (ALK inhibitors). It aims to see if this new drug can control the cancer and be safe.
Houston, TexasAges 18 years+ - NCT07308106RecruitingPhase 2
Testing SKB571 for MET-mutated advanced lung cancer
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
ShanghaiAges 18–75 - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT05701176Recruiting
Imaging scan to see how anti–PD-1 changes lung cancer cells
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
AmsterdamAges 18 years+ - NCT02421718Recruiting
Follow-up program for lung cancer and related conditions after radiation
This trial studies a standard follow-up plan to help you stay on track after radiation treatment for lung cancers or certain related conditions. It may help your care team monitor symptoms and outcomes in a consistent way.
Groningen, Provincie GroningenAges 18 years+ - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
La Jolla, CaliforniaAges 18 years+ - NCT04375904RecruitingPhase 2
Stereotactic radiation for central lung tumors
This trial tests a precise, high-dose radiation treatment aimed at central lung tumors. It may help people who cannot have lung surgery and whose tumors can be safely targeted near sensitive organs.
DublinAges 18 years+ - NCT06967532Recruiting
Using a virus to predict how well lung cancer treatment works
This study checks if a common virus (Torque Teno virus) can help predict how well immune checkpoint inhibitor therapy works for non-small cell lung cancer (NSCLC) and what happens after surgery. The goal is to find a better way to match treatment to patients.
ViennaAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (nsclc)?
- Yes. Clin2 currently lists 1,079 recruiting lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.